Levosimendan and severe pulmonary hypertension during open heart surgery.
Weaning from cardiopulmonary bypass is the most important stage during mitral valve surgery, especially in patients with severe pulmonary hypertension. We report two patients with severe pulmonary hypertension who were operated on because of valvular heart disease. To reduce the pulmonary artery pressure, levosimendan was used because of its vasodilatory and cytoprotective effects. All patients tolerated the operation and levosimendan administration. Their postoperative course was uneventful. Levosimendan can be used to treat pulmonary hypertension during operations for heart valve disease. Patients clearly benefit from the vasodilator action of the drug for reducing pulmonary artery pressure.
Cicekcioglu
Ferit
F
Kalp ve Damar Cerrahisi Klinigi (Cardiovascular Surgery Clinic), Turkiye Yuksek Ihtisas Hastanesi, Sihhiye, Ankara 06100, Turkey.
Parlar
Ali Ihsan
AI
Ersoy
Ozgur
O
Yay
Kerem
K
Hijazi
Alaa
A
Katircioglu
S Fehmi
SF
D006348:Cardiac Surgical Procedures; D005260:Female; D005500:Follow-Up Studies; D006349:Heart Valve Diseases / Q000601:surgery*; D019918:Heart Valve Prosthesis Implantation; D006801:Humans; D006835:Hydrazones / Q000008:administration & dosage / Q000627:therapeutic use*; D006976:Hypertension, Pulmonary / Q000188:drug therapy*; D008875:Middle Aged; D011724:Pyridazines / Q000008:administration & dosage / Q000627:therapeutic use*; D000077464:Simendan; D013997:Time Factors; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use*
D006835:Hydrazones; D011724:Pyridazines; D014665:Vasodilator Agents; D000077464:Simendan